PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Arovella Therapeutics Limited (ALA.AX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINAU0000182784
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapA$157.77M
EPS (TTM)-A$0.01
Total Revenue (TTM)A$980.31K
Gross Profit (TTM)-A$491.95K
EBITDA (TTM)-A$7.94M
Year RangeA$0.06 - A$0.19
Target PriceA$0.14

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Arovella Therapeutics Limited

Performance

Performance Chart

The chart shows the growth of an initial investment of A$10,000 in Arovella Therapeutics Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%MarchAprilMayJuneJulyAugust
-94.90%
278.34%
ALA.AX (Arovella Therapeutics Limited)
Benchmark (^GSPC)

S&P 500

Returns By Period

Arovella Therapeutics Limited had a return of 30.43% year-to-date (YTD) and 206.12% in the last 12 months. Over the past 10 years, Arovella Therapeutics Limited had an annualized return of -17.31%, while the S&P 500 had an annualized return of 10.83%, indicating that Arovella Therapeutics Limited did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date30.43%17.24%
1 month-9.09%2.35%
6 months-13.04%10.30%
1 year206.12%24.34%
5 years (annualized)9.86%13.87%
10 years (annualized)-17.31%10.83%

Monthly Returns

The table below presents the monthly returns of ALA.AX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202426.09%13.79%-9.09%-16.67%-4.00%16.67%17.86%30.43%
202317.39%14.81%41.94%70.45%-36.00%4.17%-16.00%47.62%9.68%30.88%3.37%25.00%400.00%
20222.56%2.50%-0.00%-4.88%-10.26%-34.29%13.04%-7.69%45.83%-14.29%-18.33%-6.12%-41.03%
20217.50%6.98%0.00%-13.04%2.50%39.02%-14.04%2.04%-6.00%-10.64%-7.14%0.00%-2.50%
2020-5.09%3.65%-14.08%-1.93%-12.53%-12.08%59.74%-2.00%-12.24%-6.98%-2.50%2.56%-18.53%
2019-8.29%-18.25%-0.00%-33.26%99.83%-47.39%33.39%12.51%-0.00%-33.37%-14.65%-9.41%-59.32%
20180.00%-6.24%-6.69%-7.13%-7.71%-33.30%-25.00%-9.12%-19.98%49.94%-0.00%-0.00%-59.10%
201714.99%-17.40%10.53%4.78%-18.19%5.54%-10.50%35.27%-8.70%-23.81%-0.00%0.00%-20.01%
20160.00%-3.69%-3.86%-11.99%0.00%-9.09%14.99%-21.74%22.23%-0.00%-4.56%-4.75%-25.92%
2015-30.51%0.00%0.00%-9.75%-21.63%-3.44%14.27%6.25%-20.59%7.41%3.44%-9.99%-54.24%
2014-17.95%-1.57%-1.58%-16.13%-1.92%-1.97%2.01%-3.92%20.40%16.95%-18.84%5.35%-24.36%
201311.77%-15.79%0.00%21.87%-23.08%-16.66%24.01%-3.24%-9.99%14.82%129.03%9.86%129.42%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of ALA.AX is 86, placing it in the top 14% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ALA.AX is 8686
ALA.AX (Arovella Therapeutics Limited)
The Sharpe Ratio Rank of ALA.AX is 8989Sharpe Ratio Rank
The Sortino Ratio Rank of ALA.AX is 8383Sortino Ratio Rank
The Omega Ratio Rank of ALA.AX is 8383Omega Ratio Rank
The Calmar Ratio Rank of ALA.AX is 8888Calmar Ratio Rank
The Martin Ratio Rank of ALA.AX is 8686Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Arovella Therapeutics Limited (ALA.AX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALA.AX
Sharpe ratio
The chart of Sharpe ratio for ALA.AX, currently valued at 1.66, compared to the broader market-4.00-2.000.002.001.66
Sortino ratio
The chart of Sortino ratio for ALA.AX, currently valued at 2.21, compared to the broader market-6.00-4.00-2.000.002.004.002.21
Omega ratio
The chart of Omega ratio for ALA.AX, currently valued at 1.29, compared to the broader market0.501.001.501.29
Calmar ratio
The chart of Calmar ratio for ALA.AX, currently valued at 1.51, compared to the broader market0.001.002.003.004.005.001.51
Martin ratio
The chart of Martin ratio for ALA.AX, currently valued at 7.15, compared to the broader market-10.000.0010.0020.007.15
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.10, compared to the broader market-4.00-2.000.002.002.10
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.87, compared to the broader market-6.00-4.00-2.000.002.004.002.87
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.501.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.85, compared to the broader market0.001.002.003.004.005.001.85
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.72, compared to the broader market-10.000.0010.0020.009.72

Sharpe Ratio

The current Arovella Therapeutics Limited Sharpe ratio is 1.66. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Arovella Therapeutics Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00MarchAprilMayJuneJulyAugust
1.66
1.79
ALA.AX (Arovella Therapeutics Limited)
Benchmark (^GSPC)

Dividends

Dividend History


Arovella Therapeutics Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%MarchAprilMayJuneJulyAugust
-98.76%
-2.39%
ALA.AX (Arovella Therapeutics Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Arovella Therapeutics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arovella Therapeutics Limited was 99.83%, occurring on Jan 9, 2023. The portfolio has not yet recovered.

The current Arovella Therapeutics Limited drawdown is 98.76%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.83%Apr 24, 20034698Jan 9, 2023
-72.86%Feb 27, 2002107Nov 18, 200214Dec 9, 2002121
-39.34%Jan 7, 200360Apr 7, 20039Apr 22, 200369
-37.84%Jan 29, 20024Feb 1, 20026Feb 11, 200210
-15.91%Dec 10, 200210Dec 27, 20024Jan 6, 200314

Volatility

Volatility Chart

The current Arovella Therapeutics Limited volatility is 29.69%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%MarchAprilMayJuneJulyAugust
29.69%
4.90%
ALA.AX (Arovella Therapeutics Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Arovella Therapeutics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Arovella Therapeutics Limited.


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items